ENDOTHELIAL MARKERS IN DIABETES MELLITUS

doi:10.1016/S0049-3848(96)00222-8

Thrombosis Research

Volume 85, Issue 1, 1 January 1997, Pages 63-65

https://doi.org/10.1016/S0049-3848(96)00222-8 Get rights and content

Abstract

In this study we examined 22 NIDDM patients without vascular complications and 17 age-matched healthy blood donors. Von Willebrand factor (vWF) levels were significantly increased in NIDDM patients compared to healthy blood donors (1.33±0.39 vs 1.01±0.27 IU/ml p=0.006), while thrombomodulin (TM) levels were similar in the both groups. vWF levels correlated with calcium dependent secretion parameters such as C-peptide (r=0.680, p<0.001) and PF4 (r=0.613, p<0.01) and did not correlate with calcium-independent markers of endothelial injury such as TM (r=0.287, p=0.196) and TFPI (r=0.296, p=0.181). Therefore it seems that increased levels of Ca_i-dependent endothelial and platelet activation markers may precede the signs of endothelial damage. This hypothesis requires further research. Copyright © 1997 Elsevier Science Ltd

Section snippets

MATERIALS AND METHODS

We examined 22 non-insulin-dependent diabetes mellitus (NIDDM) patients (12 men, 10 women, mean age 51.8±8.1 years, duration of diabetes less than 2 years) and 17 age-matched healthy blood donors (15 men, 2 women). In NIDDM group there were patients without vascular complications (without retinopathy and nephropathy), with normal endothelial injury markers (TM<50 ng/ml, TFPI <100 ng/ml) and with glycosylated hemoglobin HBA1c <10%.

Von Willebrand factor (vWF), thrombomodulin (TM) and platelet

RESULTS

Table 1 shows endothelial marker levels in diabetic patients without vascular complications and age-matched control group. vWF levels were significantly increased in NIDDM patients compared to healthy blood donors (p=0.006).

vWF levels correlated with calcium dependent secretion parameters such as CP (r=0.680, p<0.001) and PF4 (r=0.613, p<0.01). vWF values did not correlate with calcium-independent markers of endothelial injury such as TM (r=0.287, p=0.196) and TFPI (r=0.296, p=0.181).

DISCUSSION

Diabetes mellitus is associated with angiopathy accompanied by increased levels of endothelial damage markers such as vWF, TF and TFPI [2], [3], [8]. While elevated TM and TFPI values are observed only in patients with endothelial injury [4], [6], arised vWF may imply also Ca_i-dependent endothelial activation [1].

In our NIDDM patients with normal TM and TFPI, vWF levels were significantly higher compared to healthy blood donors and correlated with other Ca_i-dependent secretion parameters as CP

References (8)

J LEVY et al.
Diabetes mellitus: A disease of abnormal cellular calcium metabolism?
Amer J Med
(1994)
A.D BLANN et al.
A reliable marker of endothelial cell dysfunction: does it exist?
Brit Haematol
(1995)
A COLLIER et al.
Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria
Diabetes
(1992)
Y IWASHIMA et al.
Elevation of plasma thrombomodulin level in diabetic patients with early diabetic nephropathy
Diabetes
(1990)

There are more references available in the full text version of this article.

Cited by (31)

Plasmatic nitric oxide, but not von Willebrand Factor, is an early marker of endothelial damage, in type 1 diabetes mellitus patients without microvascular complications
2003, Journal of Diabetes and its Complications
Type 1 diabetes mellitus (IDDM) is associated with coronary artery disease and microvascular damage. Long-term glycemic control reduces but not fully prevents such complications. Recent evidence suggests that microvascular disease associated to IDDM begins with endothelial dysfunction. In this study, we evaluated changes in levels of nitric oxide (NO) and von Willebrand Factor (vWF) to detect early endothelial dysfunction in IDDM patients recently diagnosed. Subjects were included in one of the following groups: Group 1 (n=14): healthy subjects; Group 2 (n=14): IDDM patients recently diagnosed (<1 year), with no clinical evidence of microvascular disease; Group 3 (n=14): IDDM patients with microvascular disease (retinopathy and nephropathy). Urinary NO metabolites were similar in Group 1 (1.45±0.13) and Group 2 (1.6±0.2 μmol/mg creatinine) (P>.05), as well as vWF (99.6±5.7% and 84.3±5.1%, Groups 1 and 2, respectively, P>.05). Plasmatic NO metabolites were lower in Groups 2 and 3 (54.6±5.1 and 50.02±13.65 nmol/ml, respectively) compared with Group 1 (91.1±6.6 nmol/ml) (P=.0005). Also, in Group 3, urinary NO metabolites were lower (0.27±0.03 μmol/mg creatinine) and vWF was higher (184±25%) than Groups 1 and 2. There is evidence of early endothelial dysfunction even in IDDM patients recently diagnosed, with good glycemic control and without systemic hypertension, dislipidemia or microvascular disease; this endothelial damage was detected as a decrease in plasmatic NO metabolite levels, before appearance of any clinical evidence of microvascular disease.
The role of platelets in diabetes-related vascular complications
2000, Diabetes Research and Clinical Practice
The contribution of platelets to the pathogenesis and progression of vascular complications in diabetes is supported by several studies. In general, platelets obtained from diabetic subjects show increased adhesiveness and an exaggerated aggregation, both spontaneous and in response to stimulating agents. The causes for this activation are multifold: altered exposure and/or abundance of glycoprotein receptors for agonists and adhesive proteins on the platelet surface, increased binding of fibrinogen, decreased membrane fluidity, altered platelet metabolism and changes in intraplatelet signalling pathways. The altered biophysical state of platelet membrane components in diabetes mellitus may be one of the major determinants of platelet hypersensitivity and hyperfunction and may contribute to impairments in various metabolic pathways, like intensified calcium mobilisation and accentuated thromboxane synthesis and release. Activated platelets interact with other cells, such as endothelial cells and leukocytes as well with the coagulation system in the process of atherosclerosis. Some studies indicated that platelet dysfunction was especially apparent in diabetic subjects with macro- or microangiopathy, while others showed that it may be related to the presence of diabetes mellitus per se. Several pharmaceutical compounds have been developed for the inhibition of platelet activation. However, aspirin treatment is cheap and effective, and aspirin remains to be the drug of choice for diabetic patients. It should be prescribed widely for patients who are at high risk of cardiovascular events.
Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus
1998, Journal of Diabetes and its Complications
The objective of this study was to determine if treatment of non–insulin-dependent diabetes mellitus (NIDDM) patients with the “insulin sensitizer” troglitazone, both as monotherapy and in combination with insulin, corrects the impaired fibrinolysis and activated coagulation associated with NIDDM. Patients participating in two clinical trials comparing troglitazone and placebo in patients with NIDDM were studied at the time of randomization and after 26 weeks of treatment. Eighteen patients were treated with troglitazone (ten in combination with insulin and eight as monotherapy) and eight were treated with placebo (four in each trial). Plasma concentrations of plasminogen activator inhibitor (PAI-1), prothrombin fragment F1+2, fibrinogen, and von Willebrand Factor (vWF) activity were measured. Plasma PAI-1 concentrations fell significantly from a mean of 68.8 ± 32.3 ng/mL to 40.4 ± 20.4 in the troglitazone treated group, but did not change significantly in the placebo treated group. Plasma PAI-1 concentrations were elevated in 15 patients treated with troglitazone and fell to normal in eight of them. There was no significant change in plasma F1+2, vWF, and fibrinogen, but plasma C-peptide and triglyceride concentrations fell significantly with troglitazone. This study demonstrates that troglitazone treatment is associated with a significant fall in plasma PAI-1 antigen concentrations in patients with NIDDM and, therefore, may have a beneficial effect on fibrinolysis.
Type 1 diabetes mellitus in the SARS-CoV-2 pandemic: Oxidative stress as a major pathophysiological mechanism linked to adverse clinical outcomes
2021, Antioxidants
Coagulatory defects in type-1 and type-2 diabetes
2019, International Journal of Molecular Sciences
Palmitate up-regulates laminin expression via ROS/integrin αvβ3 pathway in HLSECs
2019, Oncotarget

View all citing articles on Scopus

View full text

ENDOTHELIAL MARKERS IN DIABETES MELLITUS

Abstract

Section snippets

MATERIALS AND METHODS

RESULTS

DISCUSSION

Amer J Med

A reliable marker of endothelial cell dysfunction: does it exist?

Brit Haematol

Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria

Diabetes

Elevation of plasma thrombomodulin level in diabetic patients with early diabetic nephropathy

Diabetes